Contact
Deborah Mulford, M.D.
View Contact & SchedulingAbout Me
My practice style is patient- and f...
My practice style is patient- and family-focused. I work closely with a multidisciplinary team to determine the best, evidence-based treatment option for each individual. My primary focus is in the treatment of cancers originating from the lung and/or head and neck region. I am a native Rochesterian and am proud to have attended the University of Rochester for medical school.
Conditions I Treat:
- Non small cell lung cancer
- Small cell lung cancer
- Neuroendocrine carcinoma
- Mesothelioma
- Head and neck malignancies
- Thyroid cancer
- Other malignancies
Certified Specialties
Medical Oncology - American Board of Internal Medicine
Faculty Appointments
Professor of Clinical Medicine - Department of Medicine, Hematology/Oncology (SMD)
Credentials
Residency & Fellowship
Fellowship, Hematology & Oncology, Memorial Sloan-Kettering Cancer Center. 2002 - 2005
Residency, Internal Medicine, New York University Langone Medical Center. 2000 - 2002
Internship, Internal Medicine, New York University Langone Medical Center. 1999 - 2000
Education
MD | University of Rochester. 1999
Awards
NIH Clinical Loan Repayment Program. 2004 - 2006
Lauri Strauss Leukemia Foundation Endowed Fellowship. 2003 - 2005
Mortimer J. Lacher Fellowship Award. 2003 - 2005
International Cancer Fellowship. 1996 - 1996
U.S. and European Patent-Photographic Apparatus for an Optical Instrument. 1991
Warner King Prize. 1990
Stearns Prize. 1989 - 1990
Eta Kappa Nu and Tau Beta Pi Engineering Honor Societies. 1988 - 1990
Tidmarsh Scholarship for Piano. 1986 - 1990
Research
Clinical Trials
Lead Researcher: Deborah Mulford MD
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (re...
Publications
Journal Articles
Hill BT, Ma S, Zent CS, Baran AM, Wallace DS, Advani AS, Winter AM, Winter JN, Gordon LI, Karmali R, Liesveld JL, Mulford DA, Rowland C, Bui A, Sportelli P, Miskin HP, Weiss MS, Friedberg JW, Barr PM
Blood advances.. 2024 January 238 (2):378-387. Epub 1900 01 01.
Lissa D, Takahashi N, Desai P, Manukyan I, Schultz CW, Rajapakse V, Velez MJ, Mulford D, Roper N, Nichols S, Vilimas R, Sciuto L, Chen Y, Guha U, Rajan A, Atkinson D, El Meskini R, Weaver Ohler Z, Thomas A
Nature communications.. 2022 April 1913 (1):2023. Epub 04/19/2022.
Roper N, Velez MJ, Chiappori A, Kim YS, Wei JS, Sindiri S, Takahashi N, Mulford D, Kumar S, Ylaya K, Trindade C, Manukyan I, Brown AL, Trepel JB, Lee JM, Hewitt S, Khan J, Thomas A
Nature communications.. 2021 June 2312 (1):3880. Epub 06/23/2021.
Komisarof J, Qiu H, Velez MJ, Mulford D
Molecular and clinical oncology.. 2021 April 14 (4):86. Epub 02/26/2021.
Komisarof J, Qiu H, Velez MJ, Mulford D
Molecular and clinical oncology.. 2021 February 14 (2):34. Epub 12/22/2020.
Fernandez KA, Allen P, Campbell M, Page B, Townes T, Li CM, Cheng H, Garrett J, Mulquin M, Clements A, Mulford D, Ortiz C, Brewer C, Dubno JR, Newlands S, Schmitt NC, Cunningham LL
The Journal of clinical investigation.. 2021 January 4131 (1)Epub 1900 01 01.
Milano MT, Bates JE, Budnik J, Qiu H, Hardy S, Cummings MA, Baumgart MA, Maggiore RJ, Mulford DA, Usuki KY
Lung cancer management.. 2020 February 259 (1):LMT25. Epub 02/25/2020.
Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D,
Lancet.. 2019 November 23394 (10212):1915-1928. Epub 11/01/2019.
Gajra A, Karim NA, Mulford DA, Villaruz LC, Matrana MR, Ali HY, Santos ES, Berry T, Ong TJ, Sanford A, Amiri K, Spigel DR
Frontiers in oncology.. 2018 8 :253. Epub 07/24/2018.
Advani AS, McDonough S, Copelan E, Willman C, Mulford DA, List AF, Sekeres MA, Othus M, Appelbaum FR
British journal of haematology.. 2014 October 167 (2):233-7. Epub 07/18/2014.
Advani AS; McDonough S; Copelan E; Willman C; Mulford DA; List AF; Sekeres MA; Othus M; Appelbaum FR.
British Journal of Hematology. 2014; Volume 167(Issue 2).
Liesveld JL, O'Dwyer K, Walker A, Becker MW, Ifthikharuddin JJ, Mulford D, Chen R, Bechelli J, Rosell K, Minhajuddin M, Jordan CT, Phillips GL
Leukemia research.. 2013 December 37 (12):1622-7. Epub 09/08/2013.
Raza A, Galili N, Mulford D, Smith SE, Brown GL, Steensma DP, Lyons RM, Boccia R, Sekeres MA, Garcia-Manero G, Mesa RA
Journal of hematology & oncology.. 2012 April 305 :18. Epub 04/30/2012.
Raza A, Galili N, Smith SE, Godwin J, Boccia RV, Myint H, Mahadevan D, Mulford D, Rarick M, Brown GL, Schaar D, Faderl S, Komrokji RS, List AF, Sekeres M
Cancer.. 2012 April 15118 (8):2138-47. Epub 09/01/2011.
Liesveld JL, Rosell KE, Bechelli J, Lu C, Messina P, Mulford D, Ifthikharuddin JJ, Jordan CT, Phillips Ii GL
Cancer investigation.. 2011 August 29 (7):439-50. Epub 1900 01 01.
Sekeres MA, Gundacker H, Lancet J, Advani A, Petersdorf S, Liesveld J, Mulford D, Norwood T, Willman CL, Appelbaum FR, List AF
Blood.. 2011 July 21118 (3):523-8. Epub 05/06/2011.
Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS, Heaney ML, Chanel S, Morgenstern A, Sgouros G, Larson SM, Scheinberg DA, Jurcic JG
Clinical cancer research : an official journal of the American Association for Cancer Research.. 2010 November 116 (21):5303-11. Epub 09/21/2010.
Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C
Leukemia research.. 2008 December 32 (12):1830-6. Epub 06/20/2008.
Laughlin TS, Becker MW, Liesveld JL, Mulford DA, Abboud CN, Brown P, Rothberg PG
The Journal of molecular diagnostics : JMD.. 2008 July 10 (4):338-45. Epub 06/13/2008.
Sequential therapy with cytarabine and bismuth-213 (213Bi)-labeled-HuM195 (anti-CD33) for acute myeloid leukemia (AML)
Mulford, D.; Pandit-Taskar, N.; McDevitt, M.; Finn, R.; Weiss, M.; Apostolidis, C.; Morgenstern, A.; Divgi, C.; Larson, S.; Scheinberg, D., Jurcic, J.;.
Blood. 2004; .
Reducing standard postremission chemotherapy in acute promyelocytic leukemia (APL) with risk-adapted therapy.
Mulford, D.; Maslak, P.; Weiss, M.; Scheinberg, D.; Jurcic, J.;.
Blood. 2003; : 619a.
Retrospective study to determine if the presence of trisomy 12 by FISH and cytogenetics is predictive of a slowly-progressive chronic lymphocytic leukemia.
Landau, H.; Mulford, D.; Jurcic, J.; Lammanna, N.; Weiss, M.
nab-Paclitaxel-Based Regimens in Underserved Patient Populations Part 2: The ABOUND.PS2 Study in Patients with NSCLC and a Performance Status of 2.
Gajra A; Karim NA; Mulford DA; Villaruz LC; Matrana MR; Haythem YA; Santos ES; Berry T; Ong TJ; Sanford A; Amiri K; Spigel DR.
Frontiers in Oncology, section Thoracic Oncology. .
Books
Cancer Chemotherapy and Biotherapy (2006)
Chapter: Monoclonal Antibody Therapies of Cancer
Authors: Scheinberg DA, Mulford DA, Jurcic JG, Junghans RP, Sgouros G.
Publisher: Baltimore: Lippincott, Williams, And Wilkins 2006
Ratings & Comments
At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.
Ratings
During this visit, did this provider spend enough time with you?
During this visit, did this provider show respect for what you had to say?
During this visit did this provider give you easy to understand information about these health questions or concerns?
During this visit, did this provider listen carefully to you?
During this visit, did this provider explain things in a way that was easy to understand?
Patient Comments
Good
Sep 14, 2024
Excellent
Jul 25, 2024
She seemed very caring
Jul 10, 2024
Dr. Mulford spends time to explain things. And I always have many questions, she takes time with me to explain until I have a clear understanding.
Apr 19, 2024
This was a follow up appt after being in the hospital from severe side-effects from the chemo I was receiving. She went over the whole situation and answered all my concerns and changed my treatment plan.
Apr 16, 2024
Liked that I was involved with selecting and modifying treatment plan depending on my side effects (Kidney function and hearing loss)
Feb 08, 2024
Dr. Mulford was very caring, compassionate, and professional.
Feb 02, 2024
Very well taken care of. Glad I chose UR Medicine. Thank you!
May 11, 2023
The doctor and her health team work and communicate well with each other and with me as the patient.
Apr 09, 2023
Good experience
Mar 19, 2023
Without Dr. Mulford and office I would probably be dead by now. I'm very happy with them.
Jan 20, 2023
So far the treatments I'm receiving seem to be working very well.
Jan 16, 2023
Dr. Mulford and her staff are the very best staff I have ever dealt with.
Jan 06, 2023
Excellent care and appreciate it very much
Dec 25, 2022
Have been treated for cancer nearly five years..If I have had questions they have been answered in a way I can understand.
Nov 17, 2022
Extremely knowledgeable, professional, about her field, very thorough.
Oct 28, 2022
Very glad she is helping me to get the necessary treatment for my cancer
Sep 03, 2022
Feel very lucky to have Strong Memorial for my cancer care. Appreciate all of the employees
Aug 18, 2022
Professional and courteous on all encounters.
Jul 07, 2022
Dr. Mulford is amazing - she has been so good with both of us during this difficult time.
Jun 06, 2022
I am thankful Dr. Mulford is my care provider for my diagnosis.
Mar 22, 2022
Dr Mulford is among the best if not THE best doctor I have had the pleasure to be treated by. Her willingness to listen and provide explanations Is unrivaled.
Mar 22, 2022